Close

Cerus Corp (CERS) Reports INTERCEPT Blood System Phase 2 Met Primary Endpoint

December 22, 2014 8:31 AM EST Send to a Friend
Cerus Corp (NASDAQ: CERS) announced that its Phase 2 clinical trial of red blood cells treated with the INTERCEPT Blood ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login